Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0NY6K)

• Drug Name: A 77636 Drug Info
• Synonyms: A77636; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.1(3,7))dec-1-yl-, hydrochloride, (1R-cis)-; UNII-WA6RGP1J4W; WA6RGP1J4W; 3-(1'-Adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; C20H27NO3.HCl; 145307-34-2; AC1Q3F7L; AC1L21MK; LS-173243; (1R)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol hydrochloride; (1r)-1-(aminomethyl)-3-(tricyclo[3.3.1.13,7]dec-1-yl)-3,4-dihydro-1h-isochromene-5,6-diol hydrochloride(1:1)

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 6603703
  ChEBI ID: CHEBI:64080
  CAS Number: CAS 778546-51-3
  TTD Drug ID: DM0NY6K

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[6]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[7]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[8]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[9]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[10]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[11]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[12]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[13]

Drug(s) Affected By D(1A) dopamine receptor (DRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[14]
Haloperidol	DM96SE0	Delirium		Approved	[15]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[16]
Pergolide mesylate	DM5GKOV	N. A.	N. A.	Approved	[17]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[15]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[20]
Methamphetamine	DMPM4SK	Anxiety		Approved	[21]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
D(1A) dopamine receptor (DRD1)	OTLZPBT7	DRD1_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002413)
• [2] Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology (Berl). 1999 Feb;142(1):51-60.
• [3] Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol. 2005 Oct;68(4):1039-48. doi: 10.1124/mol.105.012153. Epub 2005 Jun 28.
• [4] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [7] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [8] Clinical pipeline report, company report or official report of Lundbeck.
• [9] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [10] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [11] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [12] Clinical pipeline report, company report or official report of Lundbeck
• [13] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [14] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [15] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [16] Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992 Jul;49(7):538-44. doi: 10.1001/archpsyc.1992.01820070032005.
• [17] Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005 Sep 6;112(10):1494-9. doi: 10.1161/CIRCULATIONAHA.105.556704. Epub 2005 Aug 29.
• [18] Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):613-8. doi: 10.1111/j.1440-1681.2010.05364.x. Epub 2010 Feb 4.
• [19] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [20] Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
• [21] Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000 Nov;5(6):664-72. doi: 10.1038/sj.mp.4000760.
• [22] Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol. 2007 Sep;21(7):718-27. doi: 10.1177/0269881106072341. Epub 2006 Nov 8.